Patents by Inventor Luisruben P. MARTINEZ

Luisruben P. MARTINEZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11976083
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: May 7, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Eda Y. Canales, Weng K. Chang, Laurent P. Debien, Petr Jansa, Jennifer A. Loyer-Drew, Luisruben P. Martinez, Stephane Perreault, Gary B Phillips, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen
  • Publication number: 20230078112
    Abstract: Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Pol?) activity, in particular inhibit Pol? activity by inhibiting ATP dependent helicase domain activity of Pol?. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Pol? such as cancer, including homologous recombination (HR) deficient cancers.
    Type: Application
    Filed: May 29, 2020
    Publication date: March 16, 2023
    Inventors: Paul A. BARSANTI, Hilary Plake BECK, Melissa FLEURY, John E. KNOX, Ethan DeNardo MCSPADDEN, Brian Thomas JONES, Luisruben P. MARTINEZ, Zhonghua PEI, Chenbo WANG
  • Publication number: 20230002412
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Application
    Filed: April 28, 2021
    Publication date: January 5, 2023
    Inventors: Eda Y. Canales, Weng K. Chang, Laurent P. Debien, Petr Jansa, Jennifer A. Loyer-Drew, Luisruben P. Martinez, Stephane Perreault, Gary B. Phillips, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen
  • Publication number: 20220098154
    Abstract: Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Pol?) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of Pol? such as cancer, including homologous recombination (HR) deficient cancers.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 31, 2022
    Inventors: Hilary Plake BECK, Michael DILLON, Brian JONES, Luisruben P. MARTINEZ, Zhonghua PEI
  • Publication number: 20210387968
    Abstract: Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Pol?) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of Pol? such as cancer, including homologous recombination (HR) deficient cancers.
    Type: Application
    Filed: January 30, 2020
    Publication date: December 16, 2021
    Inventors: Hilary Plake BECK, Michael DILLON, Brian JONES, Luisruben P. MARTINEZ